Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
1.650
+0.090 (5.77%)
At close: May 8, 2026, 4:00 PM EDT
1.601
-0.049 (-2.99%)
After-hours: May 8, 2026, 7:44 PM EDT
Dogwood Therapeutics Employees
Dogwood Therapeutics had 8 employees as of December 31, 2025. The number of employees decreased by 4 or -33.33% compared to the previous year.
Employees
8
Change (1Y)
-4
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,439,254
Market Cap
55.11M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | -4 | -33.33% |
| Dec 31, 2024 | 12 | 8 | 200.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | -1 | -20.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 119 |
| BeyondSpring | 44 |
| MiNK Therapeutics | 23 |
| Entera Bio | 22 |
| iBio, Inc. | 20 |
| ImageneBio | 15 |
| Instil Bio | 14 |
| Kezar Life Sciences | 9 |
DWTX News
- 3 days ago - Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - GlobeNewsWire
- 17 days ago - Dogwood announces commercialization partnership with PRIDCor - TheFly
- 17 days ago - Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M - GlobeNewsWire
- 25 days ago - Dogwood announces FDA acceptance of SP16 investigational new drug application - TheFly
- 25 days ago - Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy - GlobeNewsWire
- 7 weeks ago - Dogwood sees cash runway into 4Q26 - TheFly
- 7 weeks ago - Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 3 months ago - Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial - TheFly